Clinical Trials Logo

Unresectable Thymic Carcinoma clinical trials

View clinical trials related to Unresectable Thymic Carcinoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03295227 Recruiting - Clinical trials for Unresectable Thymic Carcinoma

Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

Start date: December 6, 2017
Phase: Phase 1
Study type: Interventional

This phase I trial studies the sides effects and best dose of pembrolizumab in treating participants with thymoma or thymic cancer that cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.